15 Companies Pitch Their Capabilities at GA-ASI’s Blue Magic Netherlands ACN Newswire

15 Companies Pitch Their Capabilities at GA-ASI’s Blue Magic Netherlands

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
美國海軍艦艇擊退葉門胡塞武裝組織在亞丁灣的襲擊 News

美國海軍艦艇擊退葉門胡塞武裝組織在亞丁灣的襲擊

(SeaPRwire) - 美國中央司令部 (CENTCOM) 表示,兩艘美國軍艦在周末擊退了伊朗支持的胡塞武裝分子對美國軍艦的襲擊。「美國海軍驅逐艦史托克代爾號 (USS Stockdale) 和奧凱恩號 (USS O’Kane) 在 11 月 30 日至 12 月 1 日通過亞丁灣期間,成功擊退了一系列胡塞發射的武器。」美國中央司令部表示:「這些驅逐艦當時正在護送三艘美國擁有、營運和註冊的商船,而這些魯莽的襲擊沒有造成任何人員傷亡,也沒有對任何船隻(民用或美國海軍)造成損害。」聲明繼續說道:「這些驅逐艦成功地攔截並擊毀了三枚反艦彈道導彈、三架單向攻擊無人機和一枚反艦巡航導彈,確保了艦船和人員的安全,以及民用船隻及其船員的安全。」「這些行動反映了中央司令部部隊持續致力於保護美國人員、地區夥伴和國際航運免受……的襲擊。」中央司令部補充道。 這次襲擊發生在美國軍隊對也門胡塞武裝的武器儲存設施進行報復性打擊幾週後。11 月中旬襲擊的設施都位於胡塞控制的領土,並存放著胡塞武裝用於攻擊美國和其他國際軍隊以及在紅海和亞丁灣航行的民用船隻的各種先進常規武器。 美國軍方資產,包括 F-35C,被用於此次行動。一位美國國防官員告訴 ,這是 F-35C 隱形戰鬥機首次用於戰鬥。這些打擊行動還旨在削弱該組織威脅該地區夥伴的能力。’ Greg Wehner 和 Liz Friden 共同撰寫了本篇報道。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
全球最大金礦藏估值830億美元,發現於中國 News

全球最大金礦藏估值830億美元,發現於中國

(SeaPRwire) - 據中國官方媒體新華社報導,世界上最大的黃金礦藏已被發現。路透社報導,黃金儲量達6000億元人民幣,相當於830億美元。新華社報導稱,湖南省地質研究所的地質學家在該國平江縣地表以下約12英里處發現了這座金礦。據報導,此次發現的區域包含40條金礦脈,總計含有300.2噸黃金資源。據新華社報導,湖南省地質科學院預測,在3000多米深處,黃金儲量超過1000噸。世界黃金協會的數據顯示,中國是全球最大的黃金生產國,2023年約佔全球產量的10%。在此次發現之前,世界上最大的黃金儲量位於南非豪登省的South Deep金礦,據《郵報》報道,其黃金儲量約為930公噸。10月份,黃金期貨價格今年以來上漲超過32%,過去一年上漲超過38%,在此過程中創下多個歷史新高。目前每盎司黃金的價格接近2674美元。過去一年,由於包括中東和烏克蘭持續衝突在內的一系列地緣政治風險,投資者紛紛將黃金視為避險資產。美國大選後美國經濟政策方向的不確定性,以及聯準會的降息計劃和長期軌跡,也推動了黃金投資。FOX Business的Eric Revell和路透社為本報告做出了貢獻。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More

格魯吉亞總理讚揚政府鎮壓抗議活動,儘管美國予以譴責 “`

(SeaPRwire) - 面對美國的譴責以及總統本人的反抗,格魯吉亞總理伊拉克利·科巴希澤週日讚揚警方鎮壓抗議者,稱這些抗議者受境外勢力指使,意圖破壞國家。格魯吉亞,這個曾是蘇聯一部分、人口370萬的國家,自執政的格魯吉亞夢想黨週四宣佈將暫停與歐盟的加入談判四年以來,便陷入危機。歐盟和美國對格魯吉亞看似背離親西方道路、轉向俄羅斯軌道的情況感到震驚。過去三天晚上,首都第比利斯發生了大規模的反政府抗議活動,警方向人群發射水炮和催淚彈。週日晚上,第比利斯還計劃舉行更多抗議活動,當地媒體報道,全國各地城鎮也正在舉行示威活動。俄羅斯安全官員德米特里·梅德韋傑夫週日表示,格魯吉亞正在發生一場企圖發動的革命。這位前俄羅斯總統在Telegram上表示,格魯吉亞「正迅速沿著烏克蘭的道路前進,走向黑暗的深淵。通常這種事情的結局都很糟糕」。梅德韋傑夫曾被視為現代化改革者,自俄羅斯全面入侵烏克蘭以來,他已將自己塑造成一名侵略性的鷹派人物,經常向基輔及其西方支持者發出嚴厲警告。克里姆林宮尚未就格魯吉亞最新的事件發表評論,但長期以來,它一直指責西方在莫斯科仍然視為其勢力範圍內的後蘇聯國家煽動革命。格魯吉亞總理科巴希澤駁回了美國的批評,美國譴責對示威者使用「過度武力」。「儘管昨天暴力團體及其境外教官施加了最嚴重的系統性暴力,但警方表現出的標準高於美國和歐洲警方,並成功地保護了國家免受另一次違反憲法秩序的企圖。」他在記者招待會上說,但沒有提供境外參與的證據。科巴希澤還淡化了華盛頓週六宣佈暫停與格魯吉亞的戰略夥伴關係的消息。他表示,這是一個「暫時的事件」,格魯吉亞將在1月份新政府上任後與新政府進行會談。加劇該國憲法危機的是,即將卸任的總統薩洛梅·祖拉比什維利——政府的批評者和格魯吉亞加入歐盟的堅定支持者——週六表示,她將拒絕在本月底任期結束時下台。祖拉比什維利表示,她將繼續留任,因為在10月反對派稱選舉舞弊的選舉中選出的新議會是非法的,無權任命她的繼任者。科巴希澤表示,他理解祖拉比什維利的「情緒狀態」。「但當然,12月29日,她必須離開她的住所,將這座建築物交給合法選舉產生的總統。」他說。格魯吉亞夢想黨提名米赫爾·卡韋拉什維利——一位前足球明星,以強硬的反西方言論聞名——為其總統候選人。國家元首將於12月14日由由議會成員和地方政府代表組成的選舉團選出。自1991年蘇聯解體以來的大部分時間裡,格魯吉亞一直強烈傾向於西方,並試圖削弱俄羅斯的影響力,格魯吉亞在2008年與俄羅斯爆發了短暫的戰爭。它被承諾最終加入歐盟,並於去年成為歐盟正式候選國。但國內反對派和西方政府越來越擔心格魯吉亞夢想黨政府日益專制和親俄的傾向。6月,它頒佈了一項法律,規定如果非政府組織從國外獲得超過20%的資金,就必須註冊為「外國代理人」。9月,議會通過了一項限制LGBT權利的法律。政府表示,它正在採取行動,以保護國家免受外國干涉,並避免像烏克蘭那樣被捲入新的戰爭。新任歐盟外交政策負責人卡婭·卡拉斯週日向示威者表示聲援。「我們與格魯吉亞人民及其選擇歐洲未來的願望站在一起。」她在X上發帖說。「我們譴責針對抗議者的暴力行為,並對執政黨發出的不尋求格魯吉亞加入歐盟的道路以及該國民主倒退的信號表示遺憾。這將會產生來自歐盟方面的直接後果。」本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
愛爾蘭大選:執政的中右翼政黨可能保住政權,但左翼政黨辛恩·費恩仍不容小覷
“` News

愛爾蘭大選:執政的中右翼政黨可能保住政權,但左翼政黨辛恩·費恩仍不容小覷 “`

(SeaPRwire) - 愛爾蘭出口民調顯示,執政的中右翼政黨可能組成聯合政府,儘管計票工作仍在週日繼續進行,左翼政黨辛恩·費恩黨仍然有機會。根據Ipsos B&A民調顯示,中右翼政黨細緻蓋爾黨是21%選民的首選,另一個中右翼政黨愛爾蘭統一黨獲得19.5%的支持率。該民調在全國訪問了5018名選民,詢問他們如何投票。這兩個在選舉前執政的聯合政府政黨,需要獲得較小政黨或獨立人士的支持,才能在擁有174個席位的愛爾蘭議會下議院(Dail)中獲得多數席位。根據民調顯示,中間偏左的反對黨辛恩·費恩黨的支持率為21.1%,該民調的誤差幅度為正負1.4個百分點。這兩個中右翼政黨尚未獲得確保多數統治所需的88個席位,組建聯合政府的談判可能會持續數週,歐洲則等待著準總統特朗普回歸可能帶來的震盪。辛恩·費恩黨在2020年大選中取得了令人驚嘆的突破,獲得了最多選票,但卻被排除在政府之外,因為愛爾蘭統一黨和細緻蓋爾黨拒絕與其合作,理由是其左翼政策以及與北愛爾蘭三十年暴力衝突期間愛爾蘭共和軍的歷史聯繫。,其目標是將愛爾蘭與獨立的愛爾蘭共和國統一,可能成為愛爾蘭議會中最大的政黨,但它可能難以獲得足夠的聯合政府夥伴來組建政府。在大選競選期間,細緻蓋爾黨和愛爾蘭統一黨都堅持表示不會與其合作。都柏林聖三一學院前政治學教授Michael Gallagher向愛爾蘭國家廣播電台(RTE)表示,根據計票結果,愛爾蘭統一黨可能獲得多達48個席位,細緻蓋爾黨獲得39個席位,使他們達到88個席位的邊緣。根據路透社報導,最明顯的聯合政府夥伴候選人是中間偏左政黨勞工黨和社會民主黨,Gallagher表示,這兩個政黨可能分別獲得8個席位。由辛恩·費恩黨領導的政府將會動搖愛爾蘭的政治——以及未來的方向。該黨已經是北愛爾蘭最大的政黨,辛恩·費恩黨在共和國執政將會在未來幾年內推動舉行愛爾蘭統一公投。該黨領袖瑪麗·盧·麥克唐納表示,辛恩·費恩黨已經「打破了愛爾蘭的政治格局」。「兩黨政治已經結束了。它已被扔進歷史的垃圾堆,這本身就意義重大,」她在都柏林的一個計票中心等待結果時告訴美聯社。「現在的問題是,我們該如何利用這一點?」民調僅提供一個指標,並沒有揭示哪些政黨將組成下屆政府。愛爾蘭使用複雜的比例代表制,該國43個選區中的每個選區都選舉幾位立法者,選民按偏好順序對候選人進行排名。因此,完整的結果可能需要一些時間才能知道。生活成本——尤其是愛爾蘭嚴峻的住房危機——是為期三週競選活動中的主要話題,,這已成為這個長期以來以移民為特徵、人口達540萬人的國家的一個焦點問題。選舉結果將顯示愛爾蘭在經歷了多年的疫情、國際不穩定和生活成本壓力後,是否會逆轉全球趨勢。在投票日之前,分析人士表示,最可能的結果是細緻蓋爾黨和愛爾蘭統一黨再次組成聯合政府。這仍然是一個可能的選擇。下一任Taoiseach(總理)的最有力競爭者是細緻蓋爾黨現任Taoiseach西蒙·哈里斯和愛爾蘭統一黨領袖米歇爾·馬丁——儘管他們的政黨表現相對平淡。哈里斯、馬丁和麥克唐納都在週六公佈的結果中再次當選為國會議員。細緻蓋爾黨候選人、即將離任政府的一位部長帕斯卡爾·多諾霍表示,大選的主要主題是「中間力量的堅守」。「大體而言,在全歐洲執政黨都難以連任的時期,這個政府內部兩個較大的政黨,尤其是細緻蓋爾黨,將會取得非常強勁的表現,」他告訴美聯社。在上一屆議會中擁有12個席位並支撐執政聯盟的綠黨承認,它將迎來令人失望的結果。在眾多獨立候選人中,有聲名狼藉的黑幫老大傑里·「和尚」·哈奇,自本月在西班牙因洗錢指控獲保釋以參加競選以來,他獲得了廣泛的支持。早期的結果顯示,他在都柏林贏得一個席位的機會很大。路透社和本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
精神健康及藥物成癮事務部長兼衛生部副部長聲明 – 9-8-8自殺危機求助熱線服務一週年 Business

精神健康及藥物成癮事務部長兼衛生部副部長聲明 – 9-8-8自殺危機求助熱線服務一週年

(SeaPRwire) - 渥太華,安大略省, 2024年11月29日 – 每一起自殺造成的生命逝去都產生深遠的影響。自殺對家庭、朋友和社區造成的漣漪效應可能是毀滅性的。我們的政府正在確保加拿大每個人都能獲得自殺預防資源和支持——無論何時何地。 今天是全加拿大9-8-8自殺及情緒危機求助熱線啟動一週年。 一年來,加拿大各地的人們都能獲得符合文化背景且具備創傷知情能力的自殺預防和情緒困擾支持,無論他們居住在哪裡。 自啟動以來,9-8-8應答者已接聽超過30萬個電話和簡訊。這個經驗豐富的合作夥伴和訓練有素的應答者網絡,在人們需要的時候,提供了無條件的支持和同情。 全國、省級、地區和地方合作夥伴以及Centre for Addiction and Mental Health是加拿大聯邦9-8-8服務的支柱。他們在人們陷入困境的時刻提供幫助,尋找確保安全的方法,並在最需要的時候提供聯繫。 攜手合作,我們可以加強自殺預防工作,減少自殺造成的生命損失,讓個人和社區獲得所需的支援。 如果您正在考慮自殺,或擔心您認識的人可能正在考慮自殺,您可以撥打或發送簡訊至9-8-8尋求全天候支持。您並不孤單,幫助就在一通電話或簡訊之遙。 Ya’ara Saks 女士,國務大臣,國會議員 資料來源 加拿大公共衛生署 Public Health Agency of Canada本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
多倫多道明銀行股東警示:ClaimsFiler提醒損失超過10萬美元的投資者注意集體訴訟案中首席原告的截止日期 – TD Business

多倫多道明銀行股東警示:ClaimsFiler提醒損失超過10萬美元的投資者注意集體訴訟案中首席原告的截止日期 – TD

(SeaPRwire) - 紐奧良, 2024年11月30日 — ClaimsFiler 是一個免費的股東信息服務,提醒投資者,如果他們在2024年2月29日至2024年10月9日(含)期間購買了多倫多道明銀行(“TD”或“公司”)(紐約證券交易所代碼:TD)的證券,他們必須在 2024年12月23日之前提交針對多倫多道明銀行的證券集體訴訟的首席原告申請。此訴訟已提交至美國紐約南部地區聯邦地區法院。 獲得幫助 TD 投資者可以訪問 或致電免費電話 (844) 367-9658。Kahn Swick & Foti, LLC 的律師可以討論您的法律選擇。 關於訴訟 TD 及其某些高管被指控在訴訟期間未能披露重要信息,違反了聯邦證券法。 在2024年10月10日,公司披露了與美國政府各實體對公司反洗錢(“AML”)計劃遵守《美國銀行保密法》(“BSA”)的調查達成的決議,其中包括支付30.9億美元的懲罰性款項,阻止 TD 的兩個美國子公司資產總額超過4340億美元的資產上限,以及“對新的銀行產品、服務、市場和商店實施更嚴格的批准流程,以確保適當考慮和減輕新計劃的 AML 風險”。 基於此消息,TD 股票價格從2024年10月9日收盤價每股63.51美元下跌至2024年10月10日的每股59.44美元,並進一步下跌至2024年10月11日的每股57.01美元。 此案為Tiessen v. The Toronto-Dominion Bank, et al.,案號 24-cv-08032。 關於 ClaimsFiler ClaimsFiler 有一個單一使命:作為信息來源,幫助散戶投資者從證券集體訴訟和解中收回他們應得的數十億美元。在 ClaimsFiler.com 上,投資者可以:(1) 免費註冊以獲取各種證券集體訴訟案件的信息和解決方案網站的訪問權限,以便他們可以及時提交自己的索賠;(2) 上傳他們的投資組合交易數據,以便獲知他們可能有經濟利益的相關證券案件;(3) 向 Kahn Swick & Foti, LLC 律師事務所提交查詢,以獲取免費的案件評估。 要了解更多關於 ClaimsFiler 的信息,請訪問 。 資料來源 ClaimsFiler本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Rad AI 報告系統徹底改變放射科:全國最大私人診所之一效率提升 48% Business

Rad AI 報告系統徹底改變放射科:全國最大私人診所之一效率提升 48%

(SeaPRwire) - AI驅動的創新將X光影像報告效率提高了48%,整體生產力提高了25%,並減輕了放射科醫生的疲勞 芝加哥, 2024年12月1日 — ,德克薩斯州最大的私立放射科診所,也是全國最大的私立放射科診所之一,正在利用轉型其運作,放射影像報告效率提高了48%,每小時RVU生產力整體提高了25%。這些令人印象深刻的成果突顯了Rad AI在生成式AI領域的長期領導地位。 銷售、市場營銷和客戶成功高級副總裁Josh Duncan表示:“令人難以置信的是,Rad AI Reporting在去年的RSNA上獲得了AuntMinnie的‘最佳新型放射科軟體’獎,而現在,在2024年,隨著我們在全國範圍內向放射科集團部署Rad AI Reporting,我們已經展示了變革性的成果。“來自RANT的反饋和結果證明了為什麼Rad AI Reporting是放射科歷史上商業化速度最快的軟體。” RANT面臨著影像數量增加和放射科醫生疲勞的挑戰。他們決定用Rad AI Reporting取代其傳統的報告解決方案,Rad AI Reporting是一種尖端的AI和雲原生報告解決方案。使用Rad AI Reporting獨特的生成式AI功能大大減少了精神疲勞,並改善了運營成果。 RANT的首席醫療信息官Nicholas Galante醫生表示:“Rad AI徹底改變了RANT,提供了徹底改變我們工作流程並提高放射科醫生滿意度的工具。這不僅僅是升級——而是我們工作流程的一場革命。” Rad AI Reporting基於Rad AI在生成式AI和高性能雲原生現代放射科軟體方面的領先地位,為放射科醫生提供“少說多做”的體驗,從而節省放射科醫生的時間並減輕認知負擔。Rad AI Reporting從一開始就注重速度、性能和準確性,它可以幫助放射科醫生以放射科醫生的風格和語言自動生成更多報告內容。此外,Rad AI Reporting的開放式架構可以與影像AI供應商和PACS公司無縫集成。 主要成果: X光影像報告效率提高48%:RANT放射科醫生在繁忙的輪班時間內每小時閱讀的X光影像數量顯著增加。 每小時RVU生產力提高25%:主要一級創傷中心生產力提高。 減輕精神疲勞:效率和生產力提高,而感知到的精神努力沒有增加。 如需了解更多信息或安排在RSNA的演示,請訪問。 關於Rad AI Rad AI是放射科生成式AI解決方案的領導者,它正在改變放射科醫生的工作方式並改善患者護理。該公司的旗艦產品Rad AI Reporting利用AI驅動技術簡化放射科報告,並使放射科醫生能夠實現更高的效率、準確性和滿意度。該公司的開創性產品Rad AI Impressions使Rad AI成為放射科生成式AI創新的領導者; 作為第一個在放射科得到廣泛採用的生成式AI應用程序,它現在已獲得數千名美國放射科醫生的信賴。Rad AI Continuity是同類產品中最全面的解決方案,提供AI驅動的患者隨訪。 Rad AI是發展最快的放射科醫生領導的AI公司,並被CB Insights(數字健康50強,AI 100強)和AuntMinnie(2023年最佳新型放射科軟體,2021年最佳新型放射科供應商)評為最有前景的醫療保健AI公司之一。Accenture在2023年12月發布的一份報告中指出,Rad AI在放射科所有私營公司中影響力得分和品牌知名度最高,鞏固了其在該領域的領導地位。 公關聯絡人:Nicole Broomhead | Rad AI +1 ‪(323) 484-5971 資料來源 Rad AI本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
VISA股東警示:ClaimsFiler提醒損失超過10萬美元的投資者注意針對Visa Inc. – V的集體訴訟案首席原告截止日期 Business

VISA股東警示:ClaimsFiler提醒損失超過10萬美元的投資者注意針對Visa Inc. – V的集體訴訟案首席原告截止日期

(SeaPRwire) - 紐奧良, 2024年11月30日 — ClaimsFiler,一個免費的股東資訊服務,提醒投資者,如果他們在2023年11月16日至2024年9月23日(含)期間購買了Visa Inc. (NYSE: V) 的證券,他們必須在 2025年1月20日之前提交首席原告申請,參與針對Visa Inc. 的證券集體訴訟。「訴訟期間」)。此訴訟已在美國加州北區聯邦地區法院提起。 尋求協助 Visa 投資者請訪問 或致電免費電話 (844) 367-9658。Kahn Swick & Foti, LLC 的律師可以討論您的法律選擇。 關於訴訟 Visa 及其某些高管被指控在訴訟期間未能披露重要資訊,違反了聯邦證券法。 在9月24日,美國司法部對公司提起了訴訟,指控其違反《謝爾曼反托拉斯法》四項,其中指控公司利用其在支付處理市場雙邊網路效應的壟斷地位,排擠小型競爭對手,鞏固其市場主導地位,並進一步濫用這種權力,強迫商家專用其支付處理平台,從而損害消費者利益。 根據此消息,Visa 股價下跌$1.48,跌幅為 5.38%,收於每股$26.03,2024年9月24日成交量異常巨大。 此案為Cai v. Visa, Inc., et al.,案號 24-cv-08220。 關於 ClaimsFiler ClaimsFiler 只有一个使命:作为信息来源,帮助散户投资者从证券集体诉讼和解中收回其应得的数十亿美元。在 ClaimsFiler.com,投资者可以:(1) 免费注册以获取各种证券集体诉讼案件的信息和结算网站,以便他们可以及时提交自己的索赔;(2) 上传他们的投资组合交易数据,以便在他们可能拥有经济利益的相关证券案件中获得通知;以及 (3) 向 Kahn Swick & Foti, LLC 律师事务所提交询问,以免费进行案件评估。 要了解有关 ClaimsFiler 的更多信息,请访问 。 資料來源 ClaimsFiler本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Themis 推出 Tathabbat:沙烏地阿拉伯首家反洗錢及KYF/KYC公司協助保護王國經濟擴張
“` Business

Themis 推出 Tathabbat:沙烏地阿拉伯首家反洗錢及KYF/KYC公司協助保護王國經濟擴張 “`

(SeaPRwire) - 沙烏地阿拉伯利雅德, 2024年12月1日 — 全球金融犯罪預防領導者 Themis 宣佈正式推出Tathabbat。這標誌著沙烏地阿拉伯合規領域的重大進展,符合2030願景以及該國推動採用世界級「了解你的金融」(KYF) 標準的目標。 Tathabbat 旨在通過提供最先進的 KYF/KYC 工具和解決方案,賦能沙烏地金融機構和指定的非金融業務和職業 (DNFBPs)。隨著沙烏地阿拉伯準備迎接2026 年金融行動工作組 (FATF) 評估,這項投資將在強化王國的反洗錢 (AML) 和反恐怖主義融資 (CFT) 框架,增強透明度和法規遵從性方面發揮至關重要的作用。 Themis 首席執行官 Dickon Johnstone 對此次擴張充滿信心:「我們在沙烏地阿拉伯的投資證明了該地區的戰略重要性。憑藉 Tathabbat,我們致力於通過為當地機構提供尖端工具來打擊金融犯罪,從而建立更安全的金融生態系統。」 Tathabbat 首席執行官 Ali Alasiri 強調了與沙烏地阿拉伯經濟目標的一致性:「沙烏地阿拉伯的 2030 年願景正在將該地區轉變為全球金融中心。我們很高興與 Themis 合作推出 Tathabbat,這將為這個快速發展市場中的企業提供必要的 KYF 支持。」 Tathabbat 的推出標誌著 Themis 堅定承諾,幫助沙烏地企業不僅滿足合規標準,而且在日益規範的世界中蓬勃發展。 更多信息,請訪問: 關於 Tathabbat Tathabbat 通過結合尖端技術、情報、研究和數據,幫助沙烏地阿拉伯的企業識別和管理「了解你的金融」(KYF) 風險。Tathabbat 由全球 AML/CTF 技術和企業情報領導者 Themis 提供支持,確保您的業務在各個層面都得到保護。註冊於沙烏地阿拉伯王國。商業登記號:1009085146。 資料來源 Themis本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Advancing the Belt and Road Initiative: The Kyrgyz Republic Ministry of Finance’s First Promotional Seminar and Non-Deal Roadshow Successfully Held ACN Newswire

Advancing the Belt and Road Initiative: The Kyrgyz Republic Ministry of Finance’s First Promotional Seminar and Non-Deal Roadshow Successfully Held

HONG KONG, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - December 2, 2024, In the context of the Belt and Road Initiative, the first Belt and Road Golden Route Series Financial Promotion Event——the Kyrgyz Republic Ministry of Finance's promotional seminar and non-deal roadshow was successfully held today in Hong Kong. The event was jointly hosted by TF International Securities Group Limited ("TF International") and China CITIC Bank International Limited ("China CITIC Bank International"), attracting numerous international investors and financial industry leaders.The Kyrgyz Republic, as one of the earliest countries to support and engage in the Belt and Road Initiative, has seen increasingly close economic and trade relations with China. Recently, TF International signed a memorandum of understanding with the Kyrgyz Republic Ministry of Finance, becoming the first Hong Kong-based Chinese securities firm to establish an official partnership with the Kyrgyz Republic Ministry of Finance. The two parties work together to promote the RMB internationalization, support the real economy, facilitate high-quality development, and reinforce Hong Kong’s position as an international financial center. The event featured distinguished guests, including Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of Kyrgyz Republic, Mr. Abdybapov Abdanbek Abdybapovich, Head of the Government Borrowing Department of Kyrgyz Republic, Mr. CHAN Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of Hong Kong S.A.R., and Mr. ZOU Chuan, CEO of TF International, as well as Mr. Andy Siow, Senior Coverage Banker, DCM, at China CITIC Bank International. They shared insights into Kyrgyzstan’s development opportunities and investment prospects in the international financial market, discussing investment opportunities and key focus areas for mutually beneficial cooperation. In his opening speech, Mr. CHAN Ho Lim, Under Secretary for Financial Services and the Treasury of Hong Kong, remarked, "Hong Kong has firmly established itself as Asia’s leading international financial centre. Our core strengths include free flow of capital and information, a robust common law system, and a simple and low tax regime, and Hong Kong enjoys preferential access to Mainland China. All these position Hong Kong as the super-connector between China and international markets, which plays a key role in promoting RMB internationalization and advancing the Belt and Road Initiative. The Kyrgyz Republic is an important partner under the Belt and Road Initiative and is certainly Hong Kong’s important trading partner in Central Asia.” He also stated that, “I would like to express my gratitude to the Kyrgyz Republic Ministry of Finance and TF International and appreciate your commitment to fostering stronger ties between Central Asia and Hong Kong. We look forward to exploring potential future collaborations with the Kyrgyz Republic that will benefit our respective markets and promote partnerships among Belt and Road nations.” As of September 1, 2024, Renminbi (RMB) has been included in the list of official daily exchange rates published by Kyrgyzstan, alongside the US dollar, euro, Russian ruble, and Kazakh tenge. This move further strengthens economic and financial cooperation between the two countries. Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of the Kyrgyz Republic, stated, "The inclusion of the RMB in the list of official daily exchange rates in Kyrgyzstan marks a new stage in the economic cooperation between the two countries. This not only provides greater convenience for international investors but also empowers the development of Kyrgyzstan's financial market. Through this promotional event, we hope to connect with more international investment institutions and jointly promote the sustainable development of the regional economy." Hong Kong, as the international financial center and the central city of the Guangdong-Hong Kong-Macao Greater Bay Area, plays an important bridging role in the Belt and Road Initiative, leveraging its diverse financing channels and close alignment with national strategies. Mr. ZOU Chuan, CEO of TF International, stated, "The Belt and Road Initiative offers significant opportunities for economic integration and development, enhancing trade across Asia, Europe, the Middle East, and beyond. As a gateway between China and the world, Hong Kong is a key hub for the internationalization of the Renminbi, facilitating its use in trade and investment, and supporting effective currency risk management for BRI projects. With ongoing economic expansion and the internationalization of the Renminbi, Hong Kong is well-positioned to emerge as the premier financing hub. As we explore upcoming opportunities, I encourage you to envision the transformative impact these initiatives can have on the Kyrgyz Republic’s development agenda and the broader economic landscape of Central Asia. Together, we can unlock new avenues for growth and collaboration." From December 3 to 6, 2024, TF International, in collaboration with China CITIC Bank International will join forces with the Kyrgyz Republic Ministry of Finance in hosting a series of non-deal roadshows in Shanghai and Beijing, further strengthening ties with the Chinese financial market. The success of today’s promotional seminar and non-deal roadshow in Hong Kong marks a new milestone in the economic cooperation between the two countries and injects fresh momentum into the high-quality development of the Belt and Road Initiative. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
共建一帶一路:吉爾吉斯斯坦國家財政部首場推介會暨非交易性路演成功舉行 ACN Newswire

共建一帶一路:吉爾吉斯斯坦國家財政部首場推介會暨非交易性路演成功舉行

香港, 2024年12月3日 - (亞太商訊 via SeaPRwire.com) - 2024年12月2日,在「一帶一路」倡議的背景下,由天風國際證券集團有限公司(以下簡稱「天風國際」)與中信銀行(國際)有限公司(以下簡稱「信銀國際」)聯合主辦的首場「一帶一路」黃金線系列金融推介會——吉爾吉斯斯坦國家財政部推介會暨非交易性路演於今日在香港圓滿舉行。本次活動吸引了眾多國際投資機構及金融行業領袖出席。吉爾吉斯斯坦作為最早支持和參與「一帶一路」倡議的國家之一,近年來與中國的經貿合作關係日益密切。近期,天風國際與吉爾吉斯斯坦國家財政部簽訂合作備忘錄,成為首家與吉爾吉斯斯坦國家財政部建立合作關係的駐港中資券商。雙方將就共同推動人民幣國際化願景,服務實體經濟,助力高質量發展,為維持並進一步鞏固香港作為國際金融中心的地位,展開更廣泛的合作。本次活動邀請了多位重量級嘉賓,包括吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生、政府借貸部主任Abdybapov Abdanbek Abdybapovich先生、香港特別行政區政府財經事務及庫務局副局長陳浩濂太平紳士,以及天風國際行政總裁鄒傳先生和信銀國際高級董事、債券資本市場、財資及環球市場Andy Siow先生。會上,嘉賓們分享了吉爾吉斯斯坦在參與國際金融市場的發展機遇與其投資前景,共同探討了雙方互利共贏的合作著力點。陳浩濂副局長在致辭中表示:「香港作為全球主要國際金融中心,具備資本與信息的自由流動、穩健的普通法制度以及單一稅制等核心優勢,同時香港與中國內地市場聯繫緊密,在促進人民幣國際化和推動『一帶一路』倡議中發揮著關鍵作用。而吉爾吉斯斯坦作為『一帶一路』倡議下的重要合作夥伴,毫無疑問,也是香港在中亞地區的重要貿易夥伴。感謝天風國際的精心組織和吉爾吉斯斯坦代表團的到訪,今天我們齊聚一堂,探討如何進一步加强中亞與香港之間的經濟合作。我們期待未來與吉爾吉斯斯坦的合作將為兩國經濟增長注入新的動力,推動『一帶一路』國家之間的多層次合作,進一步促進區域經濟的可持續發展。」自2024年9月1日起,人民幣已正式列入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單,與美元、歐元、俄羅斯盧布和哈薩克斯坦堅戈一起,成為吉爾吉斯斯坦每日公佈匯率的貨幣,這一舉措進一步深化了兩國在經濟與金融領域的合作。吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生在會上表示:「人民幣成功納入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單,標誌著兩國經濟合作進入了新的階段。這不僅為國際投資者提供了更多便利,也為吉爾吉斯斯坦的金融市場發展賦能。我們希望通過此次推介會,與更多國際投資機構建立聯繫,共同推動區域經濟的可持續發展。」香港作為國際金融中心,同時也是粵港澳大灣區的核心城市,憑藉多樣的融資渠道和與國家戰略的深度對接,在「一帶一路」倡議中發揮了重要的橋梁作用。作為此次活動的聯合主辦方之一,天風國際行政總裁鄒傳先生在致辭中提到:「『一帶一路』倡議為經濟一體化和發展提供了巨大機遇,推動亞歐、中東乃至更廣泛地區的貿易往來。香港作為中國市場聯通世界的重要窗口,同時也是人民幣國際化的關鍵樞紐,促進人民幣在貿易和投資中的使用,支持『一帶一路』項目的融資與匯率風險管理。隨著人民幣國際化的推進,香港正穩步成為全球領先的融資中心。在探索未來機遇的同時,期待今日的活動與市場洞察的深入分享,對吉爾吉斯斯坦發展進程以及中亞經濟帶來積極、深遠的影響。」後續,天風國際聯合信銀國際將陪同吉爾吉斯斯坦國家財政部於12月3日至6日期間,陸續在上海和北京繼續舉辦系列非交易性路演活動,進一步深化吉爾吉斯斯坦與中國金融市場的聯繫。此次香港推介會的成功舉辦標誌著兩國在經濟領域合作邁向新高度,為「一帶一路」倡議的高質量發展注入了新動能。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions ACN Newswire

#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Honda Introduces AI-powered Social Robot, Haru, to University Hospital in Spain JCN Newswire

Honda Introduces AI-powered Social Robot, Haru, to University Hospital in Spain

TOKYO, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - Honda Research Institute Japan Co., Ltd. (HRI-JP), a Honda R&D subsidiary responsible for the research of cutting-edge technologies, has officially introduced its AI-powered social robot named “Haru” at the Virgen del Rocío University Hospital (HUVR) in Seville, Spain, to enhance the well-being of children while in the hospital.At the Annual Gala against Childhood Cancer, held on November 28 local time, at Casino de la Exposicion in Seville, Spain, the HUVR introduced Haru as one of the projects HUVR is implementing to improve the lives of children with cancer, who are in the hospital for long-term treatment.AI-powered social robot, HaruHRI-JP has been developing Haru, an AI-powered social robot, as a “tangible AI system” striving to realize a society where robots coexist as partners of people and to facilitate communications that create connections among people. Haru was designed to be a social robot that makes people smile through expressive communications and forms empathetic relationships with people. As a compact desk-top robot with a total height of 30cm (12 inches), Haru can be placed on a table to engage in communications with people.Haru obtains biometric information of the user, such as facial expressions and voice tones, through its built-in camera and microphones, then analyzes the information obtained to understand the user’s current state, and interacts with each user in accordance with the result of analysis, using empathetic expressions and emotionally supportive responses. Moreover, Haru can also be linked to a wristwatch-type wearable sensor worn by the user and analyze the user’s conditions in greater detail.Furthermore, as a robot, Haru does not have any human attributes such as gender, race or nationality, and is always capable of communicating from a neutral perspective, enabling Haru to effectively facilitate communication beyond generational and cultural differences, especially in group communication.HUVR had been conducting a demonstration experiment using Haru in the pediatric oncology ward of the hospital since 2021 for the purpose of enhancing both the clinical and emotional care of young patients. Since the results of the experiment have confirmed a certain level of positive effects on children with cancer, the official decision was made to advance the project with full-fledged utilization of Haru, introducing 10 units to be used in various situations in the children’s daily lives in the pediatric oncology unit.Key results of the demonstration experiment at the HUVR1. Assisting emotional and cognitive assessmentsHaru has been assisting the hospital’s neuropsychologists in conducting emotional and cognitive assessments. Using AI technology, Haru communicates with children; analyzes their biometric information, such as facial expressions and voice tones, obtained through its built-in cameras and microphones; and assist neuropsychologists in conducting emotional and cognitive assessments.Due to the amount of time the assessment takes, there is a limit to the number of assessments the neuropsychologists can conduct each year: the number had been limited to 510 per year including follow-up consultations until now. With the introduction of Haru, the number of assessments the hospital can conduct each year is expected to increase to as many as 4,500.2. Assisting rehabilitation activitiesHaru has been supporting intellectual and physical rehabilitation programs provided to young patients at the hospital. Haru learns the rehabilitation programs and can guide the children through the process while engaging them in conversation. The demonstration experiment showed that 95% of children were more actively engaged in rehabilitation while receiving guidance from Haru, compared to conventional human guides.3. Serving as a companion in playrooms and hospital roomsYoung patients who undergo long-term hospital stays for treatment spend a lot of time alone in their rooms. By communicating with the children, Haru can offer entertainment and cognitive stimulation, and help to soothe their feeling of loneliness, contributing to the enhancement of emotional care the hospital provides.4. Offering educational supportHaru connects the hospital rooms of the children who have not been able to attend school with the classrooms of their schools online, and facilitates the communication as an intermediary. This provides children at the hospital with opportunity to receive education together with children in the classroom and to interact with each other among children.Comments by the Virgen del Rocío University Hospital in Seville (HUVR)“We have been conducting joint research with HRI-JP for several years now, and gained wonderful results. We have identified that Haru holds great potential in bringing happiness to children. Typically, technologies used in hospitals focus on medical treatments or physical well-being. However, Haru has positive psychological effect of lightening the mood of our young patients and also contributes to the well-being of the hospital as a whole. The support that Haru provides, enabling children under hospital care to feel more happiness and connection with others, is unique only to Haru and offers valuable benefits not found in traditional medical care. We believe that Haru is a groundbreaking presence that creates an environment where young patients can enjoy their time here at our hospital.”Comments by Satoshi Shigemi, Honda Research Institute Japan Co., Ltd. (HRI-JP)“Based on the founding spirit of Honda, ‘using our technology to help people’ and ‘understanding people is the very essence of Honda monozukuri (art of making things),’ Honda Research Institute has been conducting research into cutting-edge technologies which have the potential to enhance positive psychological effects of people and the overall well-being of society. We are delighted by the result of our joint research with Virgen del Rocío University Hospital that shows Haru has been able to be a companion to the children at the hospital, lifting up their spirits, and bringing smiles to their faces. Moving forward, we will continue our efforts to further advance Haru as a robot which can co-exist with people 24/7 and be more helpful to young patients as well as all hospital staff to contribute to the well-being of the hospital a whole.”About Honda Research Institute (HRI)HRI was established in 2003 as a research operation which will go beyond the framework of the traditional business domain of the Honda Group and take on challenges to address issues facing humanity. Each of three HRI operations, located in Japan, the United States, and Germany, is engaged in “frontier research” with a focus on next-generation AI, including the exploration of new technologies such as quantum technology. By using Pasteur's Quadrant approach to research, which calls for the simultaneous pursuit of principles, or science, and real-world applications, HRI is striving to quickly give shape to new technologies and ideas, and create new value that can be useful to society. The research outcomes generated by HRI will lead toward the development of future Honda technologies in a wide range of technology fields, including but not limited to the areas of safety, the environment and next-generation mobility.Honda Research Institute Japan Co., Ltd. (HRI-JP), a Honda R&D subsidiary responsible for the research of cutting-edge technologies, has officially introduced its AI-powered social robot named “Haru” at the Virgen del Rocío University Hospital (HUVR) in Seville, Spain, to enhance the well-being of children while in the hospital.At the Annual Gala against Childhood Cancer, held on November 28 local time, at Casino de la Exposicion in Seville, Spain, the HUVR introduced Haru as one of the projects HUVR is implementing to improve the lives of children with cancer, who are in the hospital for long-term treatment.AI-powered social robot, HaruHRI-JP has been developing Haru, an AI-powered social robot, as a “tangible AI system” striving to realize a society where robots coexist as partners of people and to facilitate communications that create connections among people. Haru was designed to be a social robot that makes people smile through expressive communications and forms empathetic relationships with people. As a compact desk-top robot with a total height of 30cm (12 inches), Haru can be placed on a table to engage in communications with people.Haru obtains biometric information of the user, such as facial expressions and voice tones, through its built-in camera and microphones, then analyzes the information obtained to understand the user’s current state, and interacts with each user in accordance with the result of analysis, using empathetic expressions and emotionally supportive responses. Moreover, Haru can also be linked to a wristwatch-type wearable sensor worn by the user and analyze the user’s conditions in greater detail.Furthermore, as a robot, Haru does not have any human attributes such as gender, race or nationality, and is always capable of communicating from a neutral perspective, enabling Haru to effectively facilitate communication beyond generational and cultural differences, especially in group communication.HUVR had been conducting a demonstration experiment using Haru in the pediatric oncology ward of the hospital since 2021 for the purpose of enhancing both the clinical and emotional care of young patients. Since the results of the experiment have confirmed a certain level of positive effects on children with cancer, the official decision was made to advance the project with full-fledged utilization of Haru, introducing 10 units to be used in various situations in the children’s daily lives in the pediatric oncology unit.Key results of the demonstration experiment at the HUVR1. Assisting emotional and cognitive assessmentsHaru has been assisting the hospital’s neuropsychologists in conducting emotional and cognitive assessments. Using AI technology, Haru communicates with children; analyzes their biometric information, such as facial expressions and voice tones, obtained through its built-in cameras and microphones; and assist neuropsychologists in conducting emotional and cognitive assessments.Due to the amount of time the assessment takes, there is a limit to the number of assessments the neuropsychologists can conduct each year: the number had been limited to 510 per year including follow-up consultations until now. With the introduction of Haru, the number of assessments the hospital can conduct each year is expected to increase to as many as 4,500.2. Assisting rehabilitation activitiesHaru has been supporting intellectual and physical rehabilitation programs provided to young patients at the hospital. Haru learns the rehabilitation programs and can guide the children through the process while engaging them in conversation. The demonstration experiment showed that 95% of children were more actively engaged in rehabilitation while receiving guidance from Haru, compared to conventional human guides.3. Serving as a companion in playrooms and hospital roomsYoung patients who undergo long-term hospital stays for treatment spend a lot of time alone in their rooms. By communicating with the children, Haru can offer entertainment and cognitive stimulation, and help to soothe their feeling of loneliness, contributing to the enhancement of emotional care the hospital provides.4. Offering educational supportHaru connects the hospital rooms of the children who have not been able to attend school with the classrooms of their schools online, and facilitates the communication as an intermediary. This provides children at the hospital with opportunity to receive education together with children in the classroom and to interact with each other among children.Comments by the Virgen del Rocío University Hospital in Seville (HUVR)“We have been conducting joint research with HRI-JP for several years now, and gained wonderful results. We have identified that Haru holds great potential in bringing happiness to children. Typically, technologies used in hospitals focus on medical treatments or physical well-being. However, Haru has positive psychological effect of lightening the mood of our young patients and also contributes to the well-being of the hospital as a whole. The support that Haru provides, enabling children under hospital care to feel more happiness and connection with others, is unique only to Haru and offers valuable benefits not found in traditional medical care. We believe that Haru is a groundbreaking presence that creates an environment where young patients can enjoy their time here at our hospital.”Comments by Satoshi Shigemi, Honda Research Institute Japan Co., Ltd. (HRI-JP)“Based on the founding spirit of Honda, ‘using our technology to help people’ and ‘understanding people is the very essence of Honda monozukuri (art of making things),’ Honda Research Institute has been conducting research into cutting-edge technologies which have the potential to enhance positive psychological effects of people and the overall well-being of society. We are delighted by the result of our joint research with Virgen del Rocío University Hospital that shows Haru has been able to be a companion to the children at the hospital, lifting up their spirits, and bringing smiles to their faces. Moving forward, we will continue our efforts to further advance Haru as a robot which can co-exist with people 24/7 and be more helpful to young patients as well as all hospital staff to contribute to the well-being of the hospital a whole.”About Honda Research Institute (HRI)HRI was established in 2003 as a research operation which will go beyond the framework of the traditional business domain of the Honda Group and take on challenges to address issues facing humanity. Each of three HRI operations, located in Japan, the United States, and Germany, is engaged in “frontier research” with a focus on next-generation AI, including the exploration of new technologies such as quantum technology. By using Pasteur's Quadrant approach to research, which calls for the simultaneous pursuit of principles, or science, and real-world applications, HRI is striving to quickly give shape to new technologies and ideas, and create new value that can be useful to society. The research outcomes generated by HRI will lead toward the development of future Honda technologies in a wide range of technology fields, including but not limited to the areas of safety, the environment and next-generation mobility.HRI-JP has been developing Haru, an AI-powered social robot, as a “tangible AI system” striving to realize a society where robots coexist as partners of people and to facilitate communications that create connections among people. Haru was designed to be a social robot that makes people smile through expressive communications and forms empathetic relationships with people. As a compact desk-top robot with a total height of 30cm (12 inches), Haru can be placed on a table to engage in communications with people.Haru obtains biometric information of the user, such as facial expressions and voice tones, through its built-in camera and microphones, then analyzes the information obtained to understand the user’s current state, and interacts with each user in accordance with the result of analysis, using empathetic expressions and emotionally supportive responses. Moreover, Haru can also be linked to a wristwatch-type wearable sensor worn by the user and analyze the user’s conditions in greater detail.Furthermore, as a robot, Haru does not have any human attributes such as gender, race or nationality, and is always capable of communicating from a neutral perspective, enabling Haru to effectively facilitate communication beyond generational and cultural differences, especially in group communication.HUVR had been conducting a demonstration experiment using Haru in the pediatric oncology ward of the hospital since 2021 for the purpose of enhancing both the clinical and emotional care of young patients. Since the results of the experiment have confirmed a certain level of positive effects on children with cancer, the official decision was made to advance the project with full-fledged utilization of Haru, introducing 10 units to be used in various situations in the children’s daily lives in the pediatric oncology unit.Key results of the demonstration experiment at the HUVR1. Assisting emotional and cognitive assessmentsHaru has been assisting the hospital’s neuropsychologists in conducting emotional and cognitive assessments. Using AI technology, Haru communicates with children; analyzes their biometric information, such as facial expressions and voice tones, obtained through its built-in cameras and microphones; and assist neuropsychologists in conducting emotional and cognitive assessments.Due to the amount of time the assessment takes, there is a limit to the number of assessments the neuropsychologists can conduct each year: the number had been limited to 510 per year including follow-up consultations until now. With the introduction of Haru, the number of assessments the hospital can conduct each year is expected to increase to as many as 4,500.2. Assisting rehabilitation activitiesHaru has been supporting intellectual and physical rehabilitation programs provided to young patients at the hospital. Haru learns the rehabilitation programs and can guide the children through the process while engaging them in conversation. The demonstration experiment showed that 95% of children were more actively engaged in rehabilitation while receiving guidance from Haru, compared to conventional human guides.3. Serving as a companion in playrooms and hospital roomsYoung patients who undergo long-term hospital stays for treatment spend a lot of time alone in their rooms. By communicating with the children, Haru can offer entertainment and cognitive stimulation, and help to soothe their feeling of loneliness, contributing to the enhancement of emotional care the hospital provides.4. Offering educational supportHaru connects the hospital rooms of the children who have not been able to attend school with the classrooms of their schools online, and facilitates the communication as an intermediary. This provides children at the hospital with opportunity to receive education together with children in the classroom and to interact with each other among children.Comments by the Virgen del Rocío University Hospital in Seville (HUVR)“We have been conducting joint research with HRI-JP for several years now, and gained wonderful results. We have identified that Haru holds great potential in bringing happiness to children. Typically, technologies used in hospitals focus on medical treatments or physical well-being. However, Haru has positive psychological effect of lightening the mood of our young patients and also contributes to the well-being of the hospital as a whole. The support that Haru provides, enabling children under hospital care to feel more happiness and connection with others, is unique only to Haru and offers valuable benefits not found in traditional medical care. We believe that Haru is a groundbreaking presence that creates an environment where young patients can enjoy their time here at our hospital.”Comments by Satoshi Shigemi, Honda Research Institute Japan Co., Ltd. (HRI-JP)“Based on the founding spirit of Honda, ‘using our technology to help people’ and ‘understanding people is the very essence of Honda monozukuri (art of making things),’ Honda Research Institute has been conducting research into cutting-edge technologies which have the potential to enhance positive psychological effects of people and the overall well-being of society. We are delighted by the result of our joint research with Virgen del Rocío University Hospital that shows Haru has been able to be a companion to the children at the hospital, lifting up their spirits, and bringing smiles to their faces. Moving forward, we will continue our efforts to further advance Haru as a robot which can co-exist with people 24/7 and be more helpful to young patients as well as all hospital staff to contribute to the well-being of the hospital a whole.”About Honda Research Institute (HRI)HRI was established in 2003 as a research operation which will go beyond the framework of the traditional business domain of the Honda Group and take on challenges to address issues facing humanity. Each of three HRI operations, located in Japan, the United States, and Germany, is engaged in “frontier research” with a focus on next-generation AI, including the exploration of new technologies such as quantum technology. By using Pasteur's Quadrant approach to research, which calls for the simultaneous pursuit of principles, or science, and real-world applications, HRI is striving to quickly give shape to new technologies and ideas, and create new value that can be useful to society. The research outcomes generated by HRI will lead toward the development of future Honda technologies in a wide range of technology fields, including but not limited to the areas of safety, the environment and next-generation mobility. Copyright 2024 JCN Newswire via SeaPRwire.com.
More
DENSO to Exhibit at “Automechanika Dubai 2024” JCN Newswire

DENSO to Exhibit at “Automechanika Dubai 2024”

KARIYA, JAPAN, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - DENSO Sales Middle East & North Africa (DSMN), a group company of DENSO Corporation, will participate in “Automechanika Dubai 2024,” held at the Dubai World Trade Centre from December 10 to 12, 2024.Established in 2010 in Dubai, DSMN serves the Middle East and North Africa regions by offering aftermarket products and services. In these regions, motorization is advancing, and vehicles tend to have longer operational lifespans. DSMN strives to provide customers and users with peace of mind and trust through high-quality products and services, contributing to the realization of a sustainable mobility society.Automechanika Dubai is the largest automotive aftermarket trade show in the Middle East and Africa. This year, over 2,200 exhibitors are expected to participate. Many visitors are businesses seeking to establish partnerships with exhibitors, and attendance is anticipated to exceed last year’s 52,469 visitors from 161 countries. The event offers an excellent opportunity to expand business possibilities, not only in the Middle East and Africa but also in regions such as West Asia and Central Asia.Through this exhibition, DSMN aims to showcase aftermarket solutions and explore opportunities for advanced technology-based products and services. Additionally, DSMN will deepen interactions with customers and partner companies, identifying new needs and pursuing tailored solutions to address regional challenges.Booth ImageDSMN Website: https://denso.ae/Please see here for more details on DSMN’s booth: https://denso.ae/events/join-us-at-automechanika-dubai-2024-celebrating-75-years-of-innovation Copyright 2024 JCN Newswire via SeaPRwire.com.
More
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia ACN Newswire

China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia

SHENZHEN, CHINA, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the "Authorization Term"). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS's product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group's strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.About ATOM THERAPEUTICSAtom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics's main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics's core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics's another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong ACN Newswire

Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p
More
Fujitsu expands global strategic collaboration agreement with AWS to promote customer digital transformation across industries JCN Newswire

Fujitsu expands global strategic collaboration agreement with AWS to promote customer digital transformation across industries

KAWASAKI, Japan, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced that it has signed a three-year global strategic collaboration agreement (SCA) with Amazon Web Services (AWS) (1). This collaboration, officially concluded on November 29, expands the existing agreements in the mobility, finance, and retail sectors to a broader range of industries .Through this collaboration, Fujitsu will combine its expertise in systems integration and its Fujitsu Uvance offering to solve societal issues with AWS’s cloud services and cloud-native architecture to accelerate customers' digital transformation (DX) and address business challenges.Additionally, with AWS’s skills training, Fujitsu aims to strengthen its delivery system by increasing the number of Fujitsu engineers who have AWS certifications from approximately 7,000 to 12,000 over the next three years and double the number of customer deals to over 800 compared to the past 3-year SCA period.BackgroundWith the target year of 2030 for achieving the United Nations Sustainable Development Goals (SDGs) approaching, Fujitsu is promoting Fujitsu Uvance, its business model that aims to increase business growth and solve societal issues.Fujitsu Uvance leverages Fujitsu's extensive technology and industry expertise to seamlessly integrate fragmented processes and data, with the aim of creating new solutions and insights for customers. To achieve this, it is crucial to move away from legacy systems and strategically utilize cloud computing with partners. By expanding strategic collaboration with AWS, the world’s most comprehensive and broadly adopted cloud, and creating a combined solution that address customers business challenges and opportunities, Fujitsu will drive digital transformation across industries.Overview of the Initiatives1. Strengthening Fujitsu’s AWS cloud migration support servicesIn addition to having customers core systems run on their mainframes and UNIX servers, which was a strategic target of the legacy modernization collaboration announced in March 2024, the two companies will strengthen migration support services for broader on-premise systems to move onto AWS. Fujitsu will provide a comprehensive set of cloud-native system integration and operation support services through Fujitsu Cloud Transformation Service and Fujitsu Cloud Managed Service (2), with technical support from AWS.2. Enhancing added value through the service integration of Fujitsu Uvance offerings and AWSFujitsu aims to enhance added value and expand the global provision of Fujitsu Uvance offerings focusing on the two pillars of Trusted Society for a prosperous and sustainable society and Digital Shifts to support customers' data-driven strategies. As part of this effort, Fujitsu has started linking the Digital Shifts offering with its Fujitsu Kozuchi AI service and Amazon Bedrock, AWS's generative AI service. For example, Fujitsu Data Intelligence Premium, an operation platform that utilizes data and AI, analyzes production line data from factories, uses AI to detect risk signs and propose countermeasures based on past cases, and converts past inspection reports into reusable structured data to visualize and share accumulated know-how in facility maintenance work within organizations. By combining business knowledge cultivated over many years with the latest technologies such as generative AI, Fujitsu will help customers improve the efficiency and the uptime of their production processes. Demonstrations of these use cases will be showcased at the Fujitsu booth during AWS re:Invent 2024 starting today in Las Vegas, US.(3)3. Reinforcing Fujitsu’s system development and delivery capabilities by increasing the number of AWS certification holdersFujitsu aims to increase the number of Fujitsu engineers who hold AWS certifications from approximately 7,000 to 12,000 over the next three years, through AWS skills training. By increasing the number of professionals who have a deep understanding of AWS cloud services, Fujitsu will accelerate the delivery of systems that realize customers' DX, doubling the number of customer deals to over 800 compared to past 3-year SCA period.Role of Fujitsu and AWS- FujitsuLeverage its customer base and system development expertise in various industries to reach enterprise and mid-market customers.Through offerings such as legacy system modernization, cloud migration and operational support, and Fujitsu Uvance, Fujitsu will support customers' DX.- AWSAWS will strengthen its technical support for Fujitsu with its solution architects and provide advisories on the use of latest AWS services such as generative AI and cloud-native architectures for diverse use cases. AWS will also provide development environments to review latest AWS services, while also offering funds for joint sales and marketing, and AWS training and certifications for Fujitsu engineers.Yoshinami Takahashi, Vice President and COO for Uvance, Fujitsu Limited comments:“We are pleased to have concluded this global strategic collaboration with AWS. By extending our strategic collaboration to a broader range of industries, we will contribute to the digital transformation of customers across industries through legacy modernization, cloud lift and shift, and the utilization of technology and data offerings from Fujitsu Uvance together with AWS."Jaime Vallés, Vice President, Asia Pacific and Japan, Amazon Web Services comments:"Since 2012, AWS and Fujitsu have supported the digital transformation of customers in the mobility, finance, and retail sectors in Japan and worldwide. Today, we are delighted to expand our strategic collaboration with Fujitsu. Together we will broaden our Digital Transformation Experience to enable a wider range of industries and leverage our shared culture of innovation to jointly address some of the world’s biggest challenges."(1) Amazon Web Services: Headquartered in Seattle, Washington, USA, CEO Matt Garman. The collaboration was concluded with Amazon Web Services Japan GK (Head Office: Shinagawa-ku, Tokyo; President: Akihiko Shirahata).(2) Fujitsu Cloud Transformation Service and Fujitsu Cloud Managed Service: Based on Fujitsu's system design, construction, and operation know-how cultivated mainly in the enterprise domain, these services realize standardization and automation of architecture patterns, ensuring high quality while achieving cost-optimized and rapid delivery. Fujitsu adopts the "AWS Well-Architected Framework" in its delivery services, which is optimized for AWS, and has obtained the "AWS Managed Service Provider (MSP)" certification, proving the soundness and high technical capability of its AWS business.(3) AWS re:Invent: AWS’s annual global conference that starts from December 2, 2024 in Las Vegas. For more information on AWS re:Invent, please visit: https://reinvent.awsevents.com/About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.
More
MeAI Sees Strong Support from Top Launchpad CEOs Following Sold-Out IDO SeaPRwire

MeAI Sees Strong Support from Top Launchpad CEOs Following Sold-Out IDO

New York, NY – December 02, 2024 – (SeaPRwire) – MeAI, a leading innovator in AI and DeSci, announces the listing of its native token, $MEAI, following a successful Initial Dex Offering (IDO). The first AI-powered Web3 lifestyle app that integrates GameFi, SocialFi, and DeSci has successfully completed its IDO, achieving record sell-outs on 6 major launchpads (Enjinstarter, Spores, Dappad, BullPerks, BRC Starter, and Vision Launch). MeAI is set to launch on the BNB chain, and recently announced the $MEAI listing on MEXC, a top tier CEX. Key Achievements: Sold-out IDO: $MEAI IDO sell-outs in record time raising over $650,000 Expansive Network: Over 60 top-tier web3 and AI partnerships Strong support: Over 100 Private and Angel Investors Strong foundations: 435,000+ followers across socials Active community: 250,000+ active users in the MeAI Mini-app 5-star rating: MeAI Mini is ranked in the Top 5 Telegram Mini Apps by BNB Chain’s DappBay The rapid success behind the completion of the MeAI IDO and token listing positions MeAI as an emerging leader in the AI and DeSci sector. Backed by industry leaders In a recent AMA hosted by MeAI, numerous launchpad CEOs came together to discuss the $MEAI IDO and their views on the project outlook. The panel unanimously agreed that MeAI is well-positioned for success, and effectively capitalizes on the rising trends in DeSci and AI in order to become a key player in the rapidly growing market. Eran Elhanani, CEO of BullPerks, a top decentralized VC and multichain launchpad, signalled his confidence in the project, highlighting the rapid sold-out performance on BullPerks as a testament to MeAI’s strong potential and long-term viability. Market demand and investor confidence was clearly present. Mustafa Guler, CEO of Vision Launch, shared his view that MeAI was ‘one to watch’ describing it as a project with immense potential. With innovative approaches and solid foundations, MeAI was described as being poised for significant growth, with traction and momentum clearly growing behind the project. A Strong vision is set MeAI has outlined its ambitious plans for the future, detailing clear goals for scaling the project. Key to its strategy will be expanding into new markets and integrating with major blockchains, both of which are essential for driving mass adoption and growing its user base. The development and release of the main MeAI app for iOS and Android is coming soon, with an MVP launch set for Q1 2025. The team has set a target of 100k+ users for the MVP and 1M users by the end of 2025. The full MeAI app, which will feature all four modules, is expected to be completed by the end of 2025. About MeAI MeAI is the first AI-powered Web3 lifestyle app that combines fun with GameFi, SocialFi, and DeSci, to enhance both your health and wealth. Turn daily routines into exciting challenges with your unique avatar, and immerse yourself in a gamified experience. Progress through quests, achieve milestones, and level up your in-app character to earn rewards through MeAI’s integrated rewards model. MeDiet – Snap pictures of your meals, let AI analyze your plate, stay healthy, and earn rewards. MeExplore – Explore the world, complete quests solo or in teams, stay active, and get rewarded. MeSocial – Connect with other players, share experiences, challenge friends, socialize, and grow together. MeGrowth – Develop yourself, expand your career, and let AI guide you towards a better life. White Paper https://meai.gitbook.io/meai-litepaper Trade $MEAI https://www.mexc.com/exchange/MEAI_USDT Social Links X: https://x.com/meai_app Discord: https://discord.com/invite/meai-903228536867946568 Telegram: https://t.me/meai_app LinkedIn: https://www.linkedin.com/company/meai-app/ YouTube: https://www.youtube.com/@meai_app Instagram: https://www.instagram.com/meai_app/ Medium: https://medium.com/@meai_app Media contact Brand: MeAI Contact: Media team Email: support@meai.app Website: https://www.meai.app/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
More
雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德(VELSIPITY(R)) ACN Newswire

雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德(VELSIPITY(R))

上海, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) -雲頂新耀(HKEX 1952.HK)是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司,今日宣佈中國香港衛生署已正式受理伊曲莫德(VELSIPITY(R))用於治療中重度活動性潰瘍性結腸炎成人患者的新藥上市許可申請(NDA)。伊曲莫德是一款每日一次口服的一線先進療法,不僅使用方便、療效佳,而且具有良好的安全性特征。伊曲莫德已於去年10月和今年2月先後在美國和歐盟獲得新藥上市批准,同時,伊曲莫德也於今年4月獲得中國澳門特別行政區藥物監督管理局批准上市,並於今年10月通過「港澳藥械通」政策在粵港澳大灣區落地。雲頂新耀首席執行官羅永慶表示:「我們非常高興看到伊曲莫德的新藥上市許可申請在中國香港獲得正式受理。自身免疫性疾病是我們的重點關注領域和重要價值的潛在增長動力。到2030年,中國的潰瘍性結腸炎患者人數預計將達到約100萬人,超過2019年患者人數的一倍以上,存在迫切且巨大的未被滿足的臨床需求。伊曲莫德已在中國澳門獲批,並通過「港澳藥械通」政策率先在粵港澳大灣區落地。今年我們預計也將在中國大陸地區遞交伊曲莫德的新藥上市許可申請。期待伊曲莫德在更多地區獲批,進一步擴大可及性,造福廣大患者。」伊曲莫德亞太臨床試驗牽頭研究者、世界胃腸病學會執行理事、亞太消化學會副主席、中國人民解放軍空軍軍醫大學附屬西京醫院吳開春教授表示:「祝賀伊曲莫德取得的這一新進展,為中國香港的患者帶來了希望。伊曲莫德具有良好的獲益-風險特征,這種新一代S1P受體調節劑通過每日一次口服的治療方案,可快速起效,並達到無激素緩解、黏膜癒合,可為中重度活動性潰瘍性結腸炎成人患者提供先進的治療選擇。我們期待伊曲莫德在大中華區及其他亞洲國家早日獲批,為患者帶來福音。」伊曲莫德的申請是基於ELEVATE UC III期註冊研究(ELEVATE UC 52和ELEVATE UC 12)的結果,該研究旨在評價既往對至少一種常規治療、生物製劑或Janus激酶(JAK)抑制劑治療失敗或不耐受的中重度活動性潰瘍性結腸炎患者,每日一次服用2mg 伊曲莫德的安全性和療效。在ELEVATE UC 52和ELEVATE UC 12中,納入了一半以上嚴重活動性潰瘍性結腸炎患者(mMS≥7),並有近三分之一患者曾接受過生物製劑或JAK抑制劑治療。伊曲莫德的UC研究也是迄今唯一納入了孤立性直腸炎患者的UC研究。這兩項隨機、雙盲、安慰劑對照研究均達到了所有主要和關鍵次要終點,安全性特征與既往研究一致。在ELEVATE UC 52研究中,第12周時,接受伊曲莫德治療的患者臨床緩解率為27.0%(安慰劑組7.0%, 差異20.0%,P
More